****Awaiting update Q4, _model can be updated per order_[1]**

MarketVIEW: Novel coronavirus [COVID-19] vaccines (CAT: VAMV086)

Product Name	:	**MarketVIEW:** Novel coronavirus [COVID-19] vaccines
Description	:	Global vaccine commercial opportunity assessment, global market forecast
Contents	:	Executive presentation (>250 slides.pdf) + 2 x MS-Excel forecast model(s) (.xls)
Therapeutic Area	:	**Novel coronavirus vaccines**
Publication date	:	Winter 2020
Catalogue No	:	VAMV086

Background

The **novel coronavirus, SARS-CoV-2** emerged from Wuhan City, Hubei Province of China in late December 2019, causing a cluster of atypical pneumonia cases among stallholders at a seafood wholesale market. The resulting respiratory disease, later referred to as **COVID-2019**, was designated by the World Health Organisation (WHO) a Public Health Emergency of International Concern (PHEIC) on the 30th January 2020 and later a global pandemic by March 11th, 2020.

COVID-19 has affected **COVID-19** has affected ~190 countries/territories with greater than 50 million confirmed cases and close to 1.3 million deaths (as of 9th November 2020), mainly in the elderly and those with chronic underlying conditions. It is predicted that a large proportion of the global population will be infected with SARS-CoV-2 causing further excess morbidity, mortality and substantial economic loss. SARS-CoV-2 is related to other coronaviruses such as MERS-CoV (2012), SARS-CoV-1 (2003) and the endemic human betacoronaviruses OC43 and HKU1 which cause the common cold.

There is no specific treatment for COVID-19. Whether widespread herd immunity can be achieved is deeply controversial. Numerous efforts are now underway to develop new prophylatic vaccines and antiviral therapeutics to address the emergence of SARS-CoV-2. For vaccines, the Coalition of Epidemic Preparedness Innovations (CEPI) is helping fund candidates including the frontrunners being developed by Moderna Therapeutics (mRNA-1273), Pfizer (BioNTech) (BNT162b2), GSK/Sanofi, Novavax and University of Oxford/AstraZeneca. Some of these have recently entered Phase III pivotal trials with now a **positive interim readout** from the Pfizer (BioNTech) candidate. Other clinical stage vaccine programs are underway in China e.g. Sinovac and Cansino Biologicals.

This **MarketVIEW** product is a comprehensive commercial evaluation containing an Executive Presentation (>225 slides) and 2 x MS Excel Workbook(s) (.xls) examining the potential (value/volume) of a prophylatic novel coronavirus vaccine to 2045. The model has three detailed deployment scenarios which include the major Western economies, emerging economies of SE Asia, LATAM and the Far East (63 countries)*. 'At risk' populations or identified target segments (based on latest understanding) are included. A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity is also provided along with a discussion of hypothetical vaccine target product profiles (TPPs). *15 are rolled up

---

[1] Subject to schedule and an appropriate agreement being made

Bringing life to vaccine strategy...   www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom   Tel. +44(0)1279 927049   e-mail: info@vaczine-analytics.com

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to the novel coronavirus in each respective market. Source materials used are literature articles, government websites, medical bodies and associations, conference and FDA meeting proceedings etc. Previously published research by **VacZine Analytics** in the fields of other coronaviruses e.g. MERS-CoV, SARS and related emergency pathogens and their planning.

PRODUCT CONTENTS:
Published May 2020 (CAT No: VAMV086)

****This product is a summary presentation (.pdf), 1 x forecast models (.xls)

Contents – Summary presentation (.pdf)[2]

Contents
Author's notes
Executive summary
[SECTION 1] Novel coronavirus vaccines: key model outputs
[SECTION 2] Novel coronavirus: disease background
[SECTION 3] Novel coronavirus: the 2019/2020 global pandemic
[SECTION 4] Novel coronavirus: background to lung antiviral immunity and host response
[SECTION 5] Novel coronavirus: R&D pipeline and competitor activity
[SECTION 6] Novel coronavirus: modelling commercial potential
[SECTION 7] Novel coronavirus: case studies to pandemic planning
References/bibliography
About **VacZine Analytics**
Disclaimer

PAGES: >250 slides fully referenced/sourced. Available in .pdf form

Contents – 2 x vaccine demand models (MS Excel-based)

Worksheets = >100 interconnected

---

[2] Full contents i.e. title per slide is proprietary and only visible on license purchase

Bringing life to vaccine strategy...

www.vaccine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44(0)1279 927049 **e-mail:** info@vaccine-analytics.com

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- o   FULL PRODUCT - USD **$contact us**/ GBP **£contact us**[#] (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 20% will be added to final invoice total
- *indicative prevailing rate will be applied on date of transaction*

On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations)

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.


VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics ® and the **"spiral logo"** are UK Registered Trademarks, 2009

Bringing life to vaccine strategy...   www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom   Tel. +44(0)1279 927049   e-mail: info@vaczine-analytics.com

BIBLIOGRAPHY

References – proprietary

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein refered to as "The Company"). (Herein [enter client name] to as "The Client").

1. All Rights Reserved. This finished research product is a licensed product. It may not be reproduced, stored in a retrieval system or transmitted in any form without the written permission of the Company **VacZine Analytics** (of division of Assay Advantage Ltd).

2. The license granted by the Company to the Client will be non-exclusive, non-transferable and should only be used for the Client business purposes at the agreed Client sites/location in accordance with this agreement. The Client will have no ownership rights over the research product.

3. Invoicing will **100%** after submission of the deliverables (.pdf) and (.xls) to the Client.

4. If not purchased on line invoices are payable within **thirty days** of the invoice date.

5. All proposals are quoted in **$USD dollars or £GBP or €euro** and invoices are to be settled in the same currency.

6. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the research product listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.

7. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.

8. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics
A division of Assay Advantage Ltd
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 927049 / +44 (0) 7952470582
E-mail: info@vacZine-analytics.com

Bringing life to vaccine strategy...

www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom Tel. +44(0)1279 927049 e-mail: info@vaczine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information, please visit our website www.vacZine-analytics.com

VacZine Analytics ® is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics ® and "the spiral logo" are UK Registered Trademarks, 2009

Bringing life to vaccine strategy...   www.vaczine-analytics.com

Carlton House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom   **Tel.** +44(0)1279 927049   **e-mail:** info@vaczine-analytics.com